Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

Thinle Chodon, Begoña Comin-Anduix, Bartosz Chmielowski, Richard C. Koya, Zhongqi Wu, Martin Auerbach, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Tara A. McCannel, Akira Ishiyama, Johannes Czernin, Caius G. Radu, Xiaoyan Wang, David W. Gjertson, Alistair J. Cochran, Kenneth Cornetta, Deborah J.L. Wong, Paula Kaplan-LefkoOmid Hamid, Wolfram Samlowski, Peter A. Cohen, Gregory A. Daniels, Bijay Mukherji, Lili Yang, Jerome A. Zack, Donald B. Kohn, James R. Heath, John A. Glaspy, Owen N. Witte, David Baltimore, James S. Economou, Antoni Ribas

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. Experimental Design: A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. Results: A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. Conclusion: Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses.

Original languageEnglish (US)
Pages (from-to)2457-2465
Number of pages9
JournalClinical Cancer Research
Volume20
Issue number9
DOIs
StatePublished - May 1 2014

Fingerprint

Adoptive Transfer
T-Cell Antigen Receptor
Dendritic Cells
Melanoma
Vaccination
Lymphocytes
T-Lymphocytes
Cell- and Tissue-Based Therapy
Neoplasms
Genetic Engineering
Cryopreservation
Research Design
Vaccines
Clinical Trials
Safety
Peptides
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. / Chodon, Thinle; Comin-Anduix, Begoña; Chmielowski, Bartosz; Koya, Richard C.; Wu, Zhongqi; Auerbach, Martin; Ng, Charles; Avramis, Earl; Seja, Elizabeth; Villanueva, Arturo; McCannel, Tara A.; Ishiyama, Akira; Czernin, Johannes; Radu, Caius G.; Wang, Xiaoyan; Gjertson, David W.; Cochran, Alistair J.; Cornetta, Kenneth; Wong, Deborah J.L.; Kaplan-Lefko, Paula; Hamid, Omid; Samlowski, Wolfram; Cohen, Peter A.; Daniels, Gregory A.; Mukherji, Bijay; Yang, Lili; Zack, Jerome A.; Kohn, Donald B.; Heath, James R.; Glaspy, John A.; Witte, Owen N.; Baltimore, David; Economou, James S.; Ribas, Antoni.

In: Clinical Cancer Research, Vol. 20, No. 9, 01.05.2014, p. 2457-2465.

Research output: Contribution to journalArticle

Chodon, T, Comin-Anduix, B, Chmielowski, B, Koya, RC, Wu, Z, Auerbach, M, Ng, C, Avramis, E, Seja, E, Villanueva, A, McCannel, TA, Ishiyama, A, Czernin, J, Radu, CG, Wang, X, Gjertson, DW, Cochran, AJ, Cornetta, K, Wong, DJL, Kaplan-Lefko, P, Hamid, O, Samlowski, W, Cohen, PA, Daniels, GA, Mukherji, B, Yang, L, Zack, JA, Kohn, DB, Heath, JR, Glaspy, JA, Witte, ON, Baltimore, D, Economou, JS & Ribas, A 2014, 'Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma', Clinical Cancer Research, vol. 20, no. 9, pp. 2457-2465. https://doi.org/10.1158/1078-0432.CCR-13-3017
Chodon, Thinle ; Comin-Anduix, Begoña ; Chmielowski, Bartosz ; Koya, Richard C. ; Wu, Zhongqi ; Auerbach, Martin ; Ng, Charles ; Avramis, Earl ; Seja, Elizabeth ; Villanueva, Arturo ; McCannel, Tara A. ; Ishiyama, Akira ; Czernin, Johannes ; Radu, Caius G. ; Wang, Xiaoyan ; Gjertson, David W. ; Cochran, Alistair J. ; Cornetta, Kenneth ; Wong, Deborah J.L. ; Kaplan-Lefko, Paula ; Hamid, Omid ; Samlowski, Wolfram ; Cohen, Peter A. ; Daniels, Gregory A. ; Mukherji, Bijay ; Yang, Lili ; Zack, Jerome A. ; Kohn, Donald B. ; Heath, James R. ; Glaspy, John A. ; Witte, Owen N. ; Baltimore, David ; Economou, James S. ; Ribas, Antoni. / Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 9. pp. 2457-2465.
@article{ad0dc31ddde7456aae0fd6e8e36fc06b,
title = "Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma",
abstract = "Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. Experimental Design: A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. Results: A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69{\%}) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. Conclusion: Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses.",
author = "Thinle Chodon and Bego{\~n}a Comin-Anduix and Bartosz Chmielowski and Koya, {Richard C.} and Zhongqi Wu and Martin Auerbach and Charles Ng and Earl Avramis and Elizabeth Seja and Arturo Villanueva and McCannel, {Tara A.} and Akira Ishiyama and Johannes Czernin and Radu, {Caius G.} and Xiaoyan Wang and Gjertson, {David W.} and Cochran, {Alistair J.} and Kenneth Cornetta and Wong, {Deborah J.L.} and Paula Kaplan-Lefko and Omid Hamid and Wolfram Samlowski and Cohen, {Peter A.} and Daniels, {Gregory A.} and Bijay Mukherji and Lili Yang and Zack, {Jerome A.} and Kohn, {Donald B.} and Heath, {James R.} and Glaspy, {John A.} and Witte, {Owen N.} and David Baltimore and Economou, {James S.} and Antoni Ribas",
year = "2014",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-13-3017",
language = "English (US)",
volume = "20",
pages = "2457--2465",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

AU - Chodon, Thinle

AU - Comin-Anduix, Begoña

AU - Chmielowski, Bartosz

AU - Koya, Richard C.

AU - Wu, Zhongqi

AU - Auerbach, Martin

AU - Ng, Charles

AU - Avramis, Earl

AU - Seja, Elizabeth

AU - Villanueva, Arturo

AU - McCannel, Tara A.

AU - Ishiyama, Akira

AU - Czernin, Johannes

AU - Radu, Caius G.

AU - Wang, Xiaoyan

AU - Gjertson, David W.

AU - Cochran, Alistair J.

AU - Cornetta, Kenneth

AU - Wong, Deborah J.L.

AU - Kaplan-Lefko, Paula

AU - Hamid, Omid

AU - Samlowski, Wolfram

AU - Cohen, Peter A.

AU - Daniels, Gregory A.

AU - Mukherji, Bijay

AU - Yang, Lili

AU - Zack, Jerome A.

AU - Kohn, Donald B.

AU - Heath, James R.

AU - Glaspy, John A.

AU - Witte, Owen N.

AU - Baltimore, David

AU - Economou, James S.

AU - Ribas, Antoni

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. Experimental Design: A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. Results: A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. Conclusion: Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses.

AB - Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. Experimental Design: A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. Results: A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. Conclusion: Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses.

UR - http://www.scopus.com/inward/record.url?scp=84899731823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899731823&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-3017

DO - 10.1158/1078-0432.CCR-13-3017

M3 - Article

C2 - 24634374

AN - SCOPUS:84899731823

VL - 20

SP - 2457

EP - 2465

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -